Literature DB >> 32910464

Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice.

A Carvajal-González1, L Jacobson1, L Clover1, M Wickremaratchi2, S Shields3, B Lang1, A Vincent1.   

Abstract

AIMS: Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a life-threatening condition often associated with highly raised serum antibodies to glycine receptors (GlyRs); these bind to the surface of large neurons and interneurons in rodent brain and spinal cord sections and, in vitro, inhibit function and reduce surface expression of the GlyRs. The effects in vivo have not been reported.
METHODS: Purified plasma IgG from a GlyR antibody-positive patient with PERM, and a healthy control (HC), was injected daily into the peritoneal cavity of mice for 12 days; lipopolysaccharide (LPS) to open the blood-brain barrier, was injected on days 3 and 8. Based on preliminary data, behavioural tests were only performed 48 h post-LPS on days 5-7 and 10-12.
RESULTS: The GlyR IgG injected mice showed impaired ability on the rotarod from days 5 to 10 but this normalized by day 12. There were no other behavioural differences but, at termination (d13), the GlyR IgG-injected mice had IgG deposits on the neurons that express GlyRs in the brainstem and spinal cord. The IgG was not only on the surface but also inside these large GlyR expressing neurons, which continued to express surface GlyR.
CONCLUSIONS: Despite the partial clinical phenotype, not uncommon in passive transfer studies, the results suggest that the antibodies had accessed the GlyRs in relevant brain regions, led to antibody-mediated internalization and increased GlyR synthesis, compatible with the temporary loss of function.
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

Entities:  

Keywords:  PERM; Progressive encephalomyelitis with rigidity and myoclonus; animal model; antibody-mediated autoimmune disease; glycine receptor; stiff person syndrome

Mesh:

Substances:

Year:  2020        PMID: 32910464      PMCID: PMC7873718          DOI: 10.1111/nan.12666

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   6.250


  43 in total

1.  Antibody purification: ammonium sulfate fractionation or gel filtration.

Authors:  Ana Cristina Grodzki; Elsa Berenstein
Journal:  Methods Mol Biol       Date:  2010

2.  Epileptogenic effects of NMDAR antibodies in a passive transfer mouse model.

Authors:  Sukhvir Wright; Kevan Hashemi; Lukasz Stasiak; Julian Bartram; Bethan Lang; Angela Vincent; A Louise Upton
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

3.  Passive transfer of streptococcus-induced antibodies reproduces behavioral disturbances in a mouse model of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection.

Authors:  K Yaddanapudi; M Hornig; R Serge; J De Miranda; A Baghban; G Villar; W I Lipkin
Journal:  Mol Psychiatry       Date:  2009-08-11       Impact factor: 15.992

4.  Disease-specific human glycine receptor alpha1 subunit causes hyperekplexia phenotype and impaired glycine- and GABA(A)-receptor transmission in transgenic mice.

Authors:  Lore Becker; Jörg von Wegerer; Johannes Schenkel; Hanns-Ulrich Zeilhofer; Dieter Swandulla; Hans Weiher
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

5.  Stiff-person syndromes: motor cortex hyperexcitability correlates with anti-GAD autoimmunity.

Authors:  Claudia Koerner; Bettina Wieland; Wiltrud Richter; Hans-Michael Meinck
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

6.  Methods to assess the development and recovery of locomotor function after spinal cord injury in rats.

Authors:  E Kunkel-Bagden; H N Dai; B S Bregman
Journal:  Exp Neurol       Date:  1993-02       Impact factor: 5.330

7.  Behavioral effects of lipopolysaccharide in rats: involvement of endogenous opioids.

Authors:  R Yirmiya; H Rosen; O Donchin; H Ovadia
Journal:  Brain Res       Date:  1994-06-13       Impact factor: 3.252

8.  Neuromyelitis optica: Passive transfer to rats by human immunoglobulin.

Authors:  Makoto Kinoshita; Yuji Nakatsuji; Takashi Kimura; Masayuki Moriya; Kazushiro Takata; Tatsusada Okuno; Atsushi Kumanogoh; Koji Kajiyama; Hiroo Yoshikawa; Saburo Sakoda
Journal:  Biochem Biophys Res Commun       Date:  2009-06-21       Impact factor: 3.575

Review 9.  Behavioral methods to study anxiety in rodents.

Authors:  Kimberly R Lezak; Galen Missig; William A Carlezon
Journal:  Dialogues Clin Neurosci       Date:  2017-06       Impact factor: 5.986

Review 10.  In vivo Mechanisms of Antibody-Mediated Neurological Disorders: Animal Models and Potential Implications.

Authors:  Maria Pia Giannoccaro; Sukhvir K Wright; Angela Vincent
Journal:  Front Neurol       Date:  2020-02-05       Impact factor: 4.003

View more
  5 in total

Review 1.  Stiff person syndrome spectrum disorders; more than meets the eye.

Authors:  Scott D Newsome; Tory Johnson
Journal:  J Neuroimmunol       Date:  2022-06-12       Impact factor: 3.221

2.  Corrigendum.

Authors: 
Journal:  Neuropathol Appl Neurobiol       Date:  2022-04       Impact factor: 6.250

Review 3.  Autoimmune Epilepsy - Novel Multidisciplinary Analysis, Discoveries and Insights.

Authors:  Mia Levite; Hadassa Goldberg
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

4.  Impaired Verbal Memory Recall in Patients With Axonal Degeneration and Serum Glycine-Receptor Autoantibodies-Case Series.

Authors:  Niels Hansen; Claudia Bartels; Winfried Stöcker; Jens Wiltfang; Dirk Fitzner
Journal:  Front Psychiatry       Date:  2022-01-28       Impact factor: 4.157

5.  Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice.

Authors:  A Carvajal-González; L Jacobson; L Clover; M Wickremaratchi; S Shields; B Lang; A Vincent
Journal:  Neuropathol Appl Neurobiol       Date:  2020-09-28       Impact factor: 6.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.